Literature DB >> 19808299

Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.

Andreia Biolo1, Sujata Ramamurthy, Lawreen H Connors, Carl J O'Hara, Hans K Meier-Ewert, Pamela T Soo Hoo, Douglas B Sawyer, David C Seldin, David S Seldin, Flora Sam.   

Abstract

BACKGROUND: Cardiac amyloidosis is characterized by amyloid infiltration resulting in extracellular matrix disruption. Amyloid cardiomyopathy due to immunoglobulin light chain protein (AL-CMP) deposition has an accelerated clinical course and a worse prognosis compared with non-light chain cardiac amyloidoses (ie, forms associated with wild-type or mutated transthyretin [TTR]). We therefore tested the hypothesis that determinants of proteolytic activity of the extracellular matrix, the matrix metalloproteinases (MMPs), and their tissue inhibitors (TIMPs) would have distinct patterns and contribute to the pathogenesis of AL-CMP versus TTR-related amyloidosis. METHODS AND
RESULTS: We studied 40 patients with systemic amyloidosis: 10 AL-CMP patients, 20 patients with TTR-associated forms of cardiac amyloidosis, ie, senile systemic amyloidosis (involving wild-type TTR) or mutant TTR, and 10 patients with AL amyloidosis without cardiac involvement. Serum MMP-2 and -9, TIMP-1, -2, and -4, brain natriuretic peptide values, and echocardiography were determined. AL-CMP and TTR-related amyloidosis groups had similar degrees of increased left ventricular wall thickness. However, brain natriuretic peptide, MMP-9, and TIMP-1 levels were distinctly elevated accompanied by marked diastolic dysfunction in the AL-CMP group versus no or minimal increases in the TTR-related amyloidosis group. Brain natriuretic peptide, MMPs, and TIMPs were not correlated with the degree of left ventricular wall thickness but were correlated to each other and to measures of diastolic dysfunction. Immunostaining of human endomyocardial biopsies showed diffuse expression of MMP-9 and TIMP-1 in AL-CMP and limited expression in TTR-related amyloidosis hearts.
CONCLUSIONS: Despite comparable left ventricular wall thickness with TTR-related cardiac amyloidosis, AL-CMP patients have higher brain natriuretic peptide, MMPs, and TIMPs, which correlated with diastolic dysfunction. These findings suggest a relationship between light chains and extracellular matrix proteolytic activation that may play an important role in the functional and clinical manifestations of AL-CMP, distinct from the other non-light chain cardiac amyloidoses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19808299      PMCID: PMC2774449          DOI: 10.1161/CIRCHEARTFAILURE.108.788687

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  43 in total

Review 1.  The systemic amyloidoses.

Authors:  R H Falk; R L Comenzo; M Skinner
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

2.  Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes.

Authors:  S W Dubrey; K Cha; M Skinner; M LaValley; R H Falk
Journal:  Heart       Date:  1997-07       Impact factor: 5.994

3.  A new amyloidogenic transthyretin variant (Val122Ala) found in a compound heterozygous patient.

Authors:  R Théberge; L Connors; J Skare; M Skinner; R H Falk; C E Costello
Journal:  Amyloid       Date:  1999-03       Impact factor: 7.141

4.  Estimation of left ventricular filling pressures using two-dimensional and Doppler echocardiography in adult patients with cardiac disease. Additional value of analyzing left atrial size, left atrial ejection fraction and the difference in duration of pulmonary venous and mitral flow velocity at atrial contraction.

Authors:  C P Appleton; J M Galloway; M S Gonzalez; M Gaballa; M A Basnight
Journal:  J Am Coll Cardiol       Date:  1993-12       Impact factor: 24.094

5.  Echocardiography-derived left ventricular end-systolic regional wall stress and matrix remodeling after experimental myocardial infarction.

Authors:  L E Rohde; M Aikawa; G C Cheng; G Sukhova; S D Solomon; P Libby; J Pfeffer; M A Pfeffer; R T Lee
Journal:  J Am Coll Cardiol       Date:  1999-03       Impact factor: 24.094

6.  Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis.

Authors:  G Takemura; Y Takatsu; K Doyama; H Itoh; Y Saito; M Koshiji; F Ando; T Fujiwara; K Nakao; H Fujiwara
Journal:  J Am Coll Cardiol       Date:  1998-03-15       Impact factor: 24.094

Review 7.  A review of the amyloidoses that infiltrate the heart.

Authors:  R E McCarthy; E K Kasper
Journal:  Clin Cardiol       Date:  1998-08       Impact factor: 2.882

8.  Estimation of left ventricular chamber and stroke volume by limited M-mode echocardiography and validation by two-dimensional and Doppler echocardiography.

Authors:  G de Simone; R B Devereux; A Ganau; R T Hahn; P S Saba; G F Mureddu; M J Roman; B V Howard
Journal:  Am J Cardiol       Date:  1996-10-01       Impact factor: 2.778

9.  Relationship between left ventricular wall thickness and left atrial size: comparison with other measures of diastolic function.

Authors:  C L Simek; M D Feldman; H L Haber; C C Wu; A R Jayaweera; S Kaul
Journal:  J Am Soc Echocardiogr       Date:  1995 Jan-Feb       Impact factor: 5.251

10.  A simple screening test for variant transthyretins associated with familial transthyretin amyloidosis using isoelectric focusing.

Authors:  L H Connors; T Ericsson; J Skare; L A Jones; W D Lewis; M Skinner
Journal:  Biochim Biophys Acta       Date:  1998-09-30
View more
  21 in total

Review 1.  Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.

Authors:  Linn Moore; Dong Fan; Ratnadeep Basu; Vijay Kandalam; Zamaneh Kassiri
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 2.  Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment.

Authors:  David C Seldin; John L Berk; Flora Sam; Vaishali Sanchorawala
Journal:  Heart Fail Clin       Date:  2011-05-20       Impact factor: 3.179

Review 3.  Microvascular dysfunction in infiltrative cardiomyopathies.

Authors:  Ornella Rimoldi; Francesco Maranta
Journal:  J Nucl Cardiol       Date:  2017-07-11       Impact factor: 5.952

4.  Cardiac amyloidosis: evolving approach to diagnosis and management.

Authors:  Hans K Meier-Ewert; Vaishali Sanchorawala; John L Berk; Frederick L Ruberg
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-12

5.  Determinants of adiponectin levels in patients with chronic systolic heart failure.

Authors:  Andreia Biolo; Rei Shibata; Noriyuki Ouchi; Shinji Kihara; Mina Sonoda; Kenneth Walsh; Flora Sam
Journal:  Am J Cardiol       Date:  2010-02-20       Impact factor: 2.778

Review 6.  Current perspectives on cardiac amyloidosis.

Authors:  Jian Guan; Shikha Mishra; Rodney H Falk; Ronglih Liao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-11-04       Impact factor: 4.733

Review 7.  How to Image Cardiac Amyloidosis: A Practical Approach.

Authors:  Sharmila Dorbala; Sarah Cuddy; Rodney H Falk
Journal:  JACC Cardiovasc Imaging       Date:  2019-10-11

Review 8.  Recent advances in the noninvasive strategies of cardiac amyloidosis.

Authors:  Lei Zhao; Quan Fang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

9.  Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis.

Authors:  Adil Yunis; Gheorge Doros; Ivan Luptak; Lawreen H Connors; Flora Sam
Journal:  Am J Cardiol       Date:  2019-04-09       Impact factor: 2.778

Review 10.  Current and future circulating biomarkers for cardiac amyloidosis.

Authors:  Marco Luciani; Luca Troncone; Federica Del Monte
Journal:  Acta Pharmacol Sin       Date:  2018-05-17       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.